logo
New Medicaid work rules put states in a bind

New Medicaid work rules put states in a bind

Axios14-07-2025
The new Medicaid work rules in President Trump's tax-and-spending law put states on a tight timetable for setting up systems to notify millions of recipients about the requirements — and to track if they're complying.
Why it matters: Previous efforts to set work rules in Georgia and Arkansas showed it could be a messy and expensive process that generally relies on outside vendors to set up the necessary infrastructure.
Georgia spent nearly $100 million to implement its rules, $55 million of which went toward building a verification system, but in two years only enrolled a fraction of those eligible. It spent $13,000 per enrollee just to sign them up.
State of play: The new law starting in 2027 will require states to condition Medicaid eligibility for able-bodied adults on working, volunteering or doing other qualifying activities for at least 80 hours per month.
States have to verify recipients' eligibility monthly and do redeterminations at least twice a year. The new law provides $200 million to states for implementation.
The technical requirements, and the compressed time frame for rolling out the rules, will likely leave many states scrambling or applying for extensions, Medicaid experts say.
The consequences of failing could be significant. Many of the nearly 12 million people expected to lose coverage under the law will do so because of red tape around work requirements and the inability to show they're complying.
64% of adults with Medicaid already work full time or part time, according to an analysis of census data by the Center on Budget and Policy Priorities.
Another 32% are caretakers or are ill or disabled, attend school, or are retired.
Between the lines: It's not just a matter of turning a switch on states' existing Medicaid systems, which can be outdated and clunky. There needs to be reliable sources of data that can be integrated in a timely way, experts say. And there's little margin for portal crashes or other technical glitches.
"[IT] systems vary from state to state ... and we know from the COVID experience that those unemployment insurance systems are incredibly antiquated in some cases," KFF CEO Drew Altman told reporters in a call last week. "The systems work ... is quite substantial" and could be expensive, he added.
Among the challenges is how to track someone's volunteer hours, or if an individual has a varying schedule, like a gig worker. There also are factors like determining the status of a behavioral health problem that could qualify for an exemption.
"It sounds simple, but when you're talking about silos, talking to one another, it's just not," Andy Schneider, a Medicaid expert at the Georgetown University McCourt School of Public Policy.
Friction point: Georgia has turned into a cautionary tale after the state won a waiver during the first Trump administration with reports that the system was plagued with backlogs of applications, erroneous messages and technical glitches, the Associated Press reported. The state recently stopped checking each month whether beneficiaries were meeting the requirement.
"The implementation costs in Georgia are very high, a lot of systems work went into this, and at the end of the day, not nearly as many people were able to enroll in coverage," said Allison Orris, director of Medicaid policy at the Center on Budget and Policy Priorities.
Similarly, when Arkansas rolled out work requirements in 2018, individuals on Medicaid were given often conflicting information via multiple letters sent to their home, said Kevin De Liban, who was formerly director of advocacy for Legal Aid of Arkansas.
It generally took hours to get through to someone at a customer call center and, often, those people were unable to definitively answer questions about exceptions, De Liban said.
"People will lose coverage. There is no way to stop people who should be eligible from losing coverage. That's the lesson of Arkansas; there will be chaos," De Liban said.
Medicaid experts say the $200 million in implementation funds are not likely to cover the administrative, operational and communications work that will be needed to roll out the rules.
States that can't do implementation in house will find a small group of contractors with experience building enrollment and verification systems with the needed scale, including Deloitte, Accenture and Maximus.
De Liban said it's more than just handing over the keys. "The states need to be prepared to sue the contractors when those systems break, because they will break," De Liban said.
What to watch: Key exceptions to the work requirements still need to be defined by Health Secretary Robert F. Kennedy Jr. by June 2026.
The law has carve-outs for a "'disabling mental disorder" "substance abuse disorder" or "serious or complex medical conditions" but doesn't lay out details — or if states will have leeway to make determinations.
Regardless how much discretion states get, Schneider said, the data systems are going to have to sort through potentially millions of names and identify those meeting the final criteria.
The bottom line: Some states may conclude it's easier and less costly to unwind their Medicaid expansions than to deal with the cost and bureaucratic hassles of administering work rules.
"The people who wrote this were not trying to make anything work. They were trying to make this as difficult as possible because they want states to dump Medicaid expansion altogether or dump as many expansion adults as possible through red tape," Schneider said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Rebalancing Pharmaceutical Pricing Without Sacrificing Innovation
Rebalancing Pharmaceutical Pricing Without Sacrificing Innovation

Forbes

time24 minutes ago

  • Forbes

Rebalancing Pharmaceutical Pricing Without Sacrificing Innovation

Medications are stored on shelves at a pharmacy on May 12, 2025 in Los Angeles, California. (Photo by) Getty Images Two weeks ago, President Trump sent letters to 17 leading pharmaceutical manufacturers, giving them 60 days to propose plans to lower U.S. drug prices to align with the lowest prices offered in other developed nations. This is an opportunity to recalibrate pharmaceutical pricing in a way that brings relief to U.S. consumers, corrects global imbalances and safeguards innovation, a transition the entire healthcare ecosystem must eventually adopt. Most discussions about drug prices focus narrowly on the retail cost patients see at the pharmacy counter, but these are only a fraction of the real economic picture. Trump's directive aims to address a decades-long imbalance: Americans pay significantly more for the same products than consumers abroad, in effect subsidizing both foreign healthcare systems and pharmaceutical profits. The 'most favored nation' concept could give consumers better pricing, but it also raises critical questions about sustaining innovation and ensuring access. By putting pharmaceutical manufacturers on the clock, the administration signals a willingness to use negotiation and policy leverage, similar to its tariff strategy, to change entrenched practices. As I've long argued in previous columns, focusing solely on high drug prices misses the larger problem: healthcare as a whole delivers too little value for what we spend. The need for transparency in both cost and quality, as well as a greater appreciation of outcomes that matter to patients, applies to every sector, from pharmaceuticals to hospital care. Pharma is a practical starting point because public attention is already here, but the real target is an ecosystem-wide business model change. Without a broad value-based framework and a clear vision of how to proceed, reforms will default to piecemeal fixes that merely shift costs from one part of the system to another. Some policymakers have advocated for blunt price caps as a quick solution to escalating drug prices. Experience shows this approach distorts markets, erodes innovation and ultimately harms patients, the topic of one of my past columns. In Europe, where prices are heavily controlled, access to new therapies can be delayed or denied, a cautionary example for the U.S. Innovation is inherently risky: only a fraction of drug candidates ever reach the market, and the returns on successful products fund the failures. Suppressing returns discourages the investment needed for breakthrough discoveries. The goal should be rebalancing—with Europe paying more, the U.S. paying less—not penalizing one of America's most important and competitive industries. The administration has made it clear it is prepared to disrupt the status quo. Disruption is most productive when it's channeled toward structural reform. Pharmaceutical pricing reform can set a precedent for other segments of healthcare—delivery systems, payers and PBMs—where misaligned incentives drive up costs without improving outcomes. Stakeholders should view the 60-day deadline not just as a compliance exercise but as an invitation to propose creative, sustainable models that link payment to measurable results. This is a rare alignment of political will, public attention and market readiness, an environment conducive to bold experimentation. If the industry responds defensively or minimally, the likely result will be more prescriptive regulation and less flexibility to innovate. Conversely, failure to address pricing inequities will keep U.S. consumers shouldering disproportionate costs, fueling political pressure for heavy-handed solutions. Past decades of incremental tweaks have left us with a fragmented, opaque system. The risk now is that we repeat that pattern rather than rethinking the fundamentals. Rebalancing pharmaceutical pricing is not about punishing one sector or enacting price controls. It's about creating a market where cost reflects value, competition rewards innovation and consumers benefit from both affordability and access. Pharmaceutical companies are simply the first to face this scrutiny, but the value conversation must extend to every corner of healthcare delivery. This moment, if met with creativity and commitment, can be a catalyst for systemic change that has eluded us for decades.

FDA may pull authorization for Pfizer COVID shot for kids under 5
FDA may pull authorization for Pfizer COVID shot for kids under 5

The Hill

timean hour ago

  • The Hill

FDA may pull authorization for Pfizer COVID shot for kids under 5

The Food and Drug Administration (FDA) is considering revoking the authorization of Pfizer's COVID-19 vaccine for healthy children under 5 years old, the company confirmed Wednesday. The move would add another barrier for parents who want to vaccinate healthy children, as shots from Moderna and Novavax were approved for more limited populations. In May, Health and Human Services Secretary Robert F. Kennedy Jr. said that the Centers for Disease Control and Prevention (CDC) would no longer recommend COVID-19 vaccines for healthy children or pregnant women. The CDC then updated its immunization schedule to reflect that children with no underlying health condition 'may receive' COVID-19 vaccines after consulting with a health care provider — what's known as 'shared decision-making.' If FDA pulls its emergency use authorization, Pfizer's vaccine would no longer be available to any children younger than 5. Right now, Moderna and Novavax shots could be administered 'off label' to healthy children. 'We are currently in discussions with the agency on potential paths forward and have requested that the EUA for this age group remain in place for the 2025-2026 season,' a Pfizer spokesman told The Hill. 'It is important to note that these deliberations are not related to the safety and efficacy of the vaccine which continues to demonstrate a favorable profile,' the company added. The Guardian first reported on the FDA's potential move. In a statement to The Hill, HHS said it wouldn't comment on potential changes. 'The COVID-19 pandemic ended with the expiration of the federal public health emergency in May 2023. We do not comment on potential, future regulatory changes. Unless officially announced by HHS, discussion about future agency action should be regarded as pure speculation,' HHS spokesman Andrew Nixon said. Pfizer has had full FDA approval for its COVID-19 vaccine for individuals age 12 and older since 2022.

CDC shooter Patrick Joseph White's dad repeatedly called 911 fearing he was gunman
CDC shooter Patrick Joseph White's dad repeatedly called 911 fearing he was gunman

New York Post

timean hour ago

  • New York Post

CDC shooter Patrick Joseph White's dad repeatedly called 911 fearing he was gunman

The father of the anti-vaxxer gunman who killed a cop when he fired more than 180 shots at the US Centers for Disease Control and Prevention repeatedly called 911 fearing that his son was responsible for the attack, newly released 911 calls show. Kenneth White had begged authorities for help as his son, Patrick Joseph White, was unleashing his reign of terror on the CDC's Atlanta headquarters last Friday, according to transcripts obtained by 11Alive. 'I'm very worried that he might have been involved in this shooting today,' the dad said in one call. Advertisement 3 Documents found in a search of the home where CDC shooter Patrick Joseph Smith lived with his parents revealed his discontent with the COVID-19 vaccinations. AP 'I can't get any information from anybody. I've called the DeKalb County 911 number three times and left detailed information, and no one ever called us back. I don't know if he was involved. I need some help.' In another call, the dad specifically asked for one officer to call back given he'd helped with his son in the past. Advertisement 'He has been involved last summer with some problems we had with my adult son,' the elder White said of the cop. '[The officer] had left me his name and number and said if you guys need anything with Patrick, give me a call.' Records show there had been at least 10 emergency calls made from the White family home over the last two years, including for suicide threats and domestic disturbances. 3 Patrick Joseph Smith fired more than 180 shots into the CDC campus in Atlanta and broke 150 windows on Friday. AP It wasn't immediately clear if authorities returned the calls from White's dad during Friday's incident. Advertisement The shooter, who authorities said blamed the COVID-19 vaccine for making him depressed and suicidal, was found dead from a self-inflicted gunshot wound shortly after his rampage. Investigators said White had broken into a locked safe to get his father's weapons before he stormed the CDC's headquarters. CDC security guards had initially stopped White from driving into the campus Friday — so he parked near a pharmacy across the street and opened fire from the sidewalk, authorities said. 3 Police vehicles near Emory University and the CDC campus in Atlanta after the shooting on Aug. 8, 2025. Getty Images Advertisement His bullets broke about 150 'blast-resistant' windows across the campus. DeKalb County Police Officer David Rose was fatally shot while responding to the rampage, according to investigators. No one inside the CDC building was injured. In the aftermath, a search warrant at White's home uncovered a slew of written documents and electronic devices that are still being analyzed. Some of the materials 'expressed the shooter's discontent with the COVID-19 vaccinations' and his desire to make 'the public aware of his discontent with the vaccine,' Georgia Bureau of Investigation Director Chris Hosey said. With Post wires

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store